We are live on ! Find out more
CM

CM Management Portfolio holdings

AUM $120M
1-Year Est. Return 37.12%
This Fund
S&P 500
This Quarter Est. Return
-2.07%
1 Year Est. Return
+37.12%
3 Year Est. Return
+141.34%
5 Year Est. Return
+139.46%
10 Year Est. Return
–
AUM
$89.6M
AUM Growth
-$4.37M
Cap. Flow
+$640K
Cap. Flow %
0.71%
Top 10 Hldgs %
36.69%
Holding
74
New
5
Increased
31
Reduced
13
Closed
3

Top Buys

1
JPM icon
JPMorgan Chase
JPM
+$1.15M
2
FDX icon
FedEx
FDX
+$1.06M
3
WBA
Walgreens Boots Alliance
WBA
+$926K
4
AI icon
C3.ai
AI
+$897K
5
B
Barrick Mining
B
+$868K

Top Sells

1
CYTK icon
Cytokinetics
CYTK
+$2.41M
2
PTCT icon
PTC Therapeutics
PTCT
+$1.8M
3
CADE
Cadence Bank
CADE
+$1.64M
4
TALO icon
Talos Energy
TALO
+$1.34M
5
PAGP icon
Plains GP Holdings
PAGP
+$1.15M

Sector Composition

1 Healthcare 37.28%
2 Financials 10.8%
3 Energy 9.75%
4 Industrials 9.02%
5 Technology 7.84%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
C icon
51
Citigroup
C
$221B
$625K 0.7%
15,000
-10,000
-40% -$494K
FIS icon
52
Fidelity National Information Services
FIS
$22B
$567K 0.63%
+7,500
New +$698K
ELTX icon
53
Elicio Therapeutics
ELTX
$84M
$552K 0.62%
60,000
+7,500
+14% +$78.4K
PAGP icon
54
Plains GP Holdings
PAGP
$5.04B
$546K 0.61%
50,000
-100,000
-67% -$1.15M
SVC
55
Service Properties Trust
SVC
$1.13B
$519K 0.58%
20,000
– –
SMSI icon
56
Smith Micro Software
SMSI
$14.4M
$486K 0.54%
5,375
+1,000
+23% +$101K
AE
57
DELISTED
Adams Resources & Energy Inc
AE
$447K 0.5%
15,000
-13,950
-48% -$428K
INTT icon
58
inTEST
INTT
$173M
$420K 0.47%
55,000
– –
GANX icon
59
Gain Therapeutics
GANX
$70.8M
$408K 0.46%
125,000
– –
BCEL
60
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$391K 0.44%
249,282
+24,282
+11% +$49.9K
RBCAA icon
61
Republic Bancorp
RBCAA
$1.81B
$383K 0.43%
10,000
-15,077
-60% -$669K
CBAY
62
DELISTED
Cymabay Therapeutics
CBAY
$350K 0.39%
100,000
-110,000
-52% -$395K
SPPI
63
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$344K 0.38%
800,000
+200,000
+33% +$197K
FEMY icon
64
Femasys
FEMY
$9.21M
$339K 0.38%
15,000
– –
AMRX icon
65
Amneal Pharmaceuticals
AMRX
$5.76B
$303K 0.34%
150,000
+50,000
+50% +$140K
LTRN icon
66
Lantern Pharma
LTRN
$37.1M
$239K 0.27%
50,000
+4,900
+11% +$26.3K
PAAS icon
67
Pan American Silver
PAAS
$17.7B
$238K 0.27%
15,000
+5,000
+50% +$87.1K
EDSA icon
68
Edesa Biotech
EDSA
$64.7M
$230K 0.26%
+35,714
New +$439K
MCLD
69
DELISTED
mCloud Technologies Corp. Common Shares
MCLD
$223K 0.25%
142,764
-52,402
-27% -$128K
NBSE
70
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
$178K 0.2%
22,500
+4,000
+22% +$66.2K
NKTR icon
71
Nektar Therapeutics
NKTR
$2.27B
$160K 0.18%
3,333
-5,000
-60% -$297K
CADE
72
DELISTED
Cadence Bank
CADE
– –
-70,000
Closed -$1.64M
CMPX icon
73
Compass Therapeutics
CMPX
$378M
– –
-30,000
Closed -$80K
PTCT icon
74
PTC Therapeutics
PTCT
$6.51B
– –
-45,000
Closed -$1.8M
1 2
3

Similar funds

AA
Ahara Advisors Jersey City, New Jersey $120M AUM
CC
Commons Capital Needham, Massachusetts $120M AUM 31.45% 1-Year Est. Return
DG
Dala Group Hoffman Estates, Illinois $120M AUM
ACM
AIHC Capital Management Central $120M AUM
WAG
Windsor Advisory Group Columbus, Ohio $120M AUM 4.29% 1-Year Est. Return
YMRC
Yorktown Management & Research Company Forest, Virginia $120M AUM 52.72% 1-Year Est. Return
IW
Integrated Wealthcare Durham, North Carolina $120M AUM
BCWM
Ball & Co Wealth Management Franklin, Tennessee $120M AUM 21.28% 1-Year Est. Return

CM Management's Q3 2022 Portfolio in Review

As of Q3 2022, CM Management held 74 positions worth $89.6M, down 4.7% from $94M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

CM Management's Q3 2022 filing shows 5 new, 31 increased, 13 reduced and 3 closed positions. Its largest new stake was JPMorgan Chase: 10,000 shares worth $1.04M. The largest sale was Cytokinetics, an estimated $2.41M.

By sector, the portfolio is most concentrated in Healthcare at 37% of assets, down from 39% a quarter earlier, followed by Financials and Energy.

  • CM Management's largest Q3 2022 buy was JPMorgan Chase: 10,000 shares worth $1.04M.
  • CM Management added most to Walgreens Boots Alliance in Q3 2022, an estimated $926K increase.
  • CM Management's biggest Q3 2022 reduction was Cytokinetics, cutting an estimated $2.41M.
  • CM Management fully exited PTC Therapeutics in Q3 2022, selling an estimated $1.8M.
  • CM Management's ten largest holdings make up 37% of its $89.6M portfolio in Q3 2022.
  • CM Management opened 5 new positions and closed 3 in Q3 2022.
  • CM Management's portfolio value fell 4.7% quarter-over-quarter to $89.6M.

Based on CM Management's 13F filing for Q3 2022, filed 4 Nov 2022.